The Discounted Cash Flow (DCF) valuation of Theravance Biopharma Inc (TBPH) is (27.78) USD. With the latest stock price at 9.45 USD, the upside of Theravance Biopharma Inc based on DCF is -394.0%.
Based on the latest price of 9.45 USD and our DCF valuation, Theravance Biopharma Inc (TBPH) is a sell. selling TBPH stocks now will result in a potential gain of 394.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 8.5% | 7.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (83.45) - (16.74) | (27.78) |
| Upside | -983.1% - -277.1% | -394.0% |